Anhui Anke Biotechnology (Group) Co., Ltd. (SHE:300009)
China · Delayed Price · Currency is CNY 9.87
-0.09 (-0.90%)
Apr 17, 2026, 3:04 PM CST
SHE:300009 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Dec '21 Dec 31, 2021 |
Operating Revenue | 2,643 | 2,533 | 2,861 | 2,327 | 2,160 |
Other Revenue | 3.19 | 2.65 | 4.57 | 4.18 | 8.5 |
| 2,647 | 2,536 | 2,866 | 2,331 | 2,169 | |
Revenue Growth (YoY) | 4.36% | -11.51% | 22.94% | 7.48% | 27.47% |
Cost of Revenue | 660.63 | 581.16 | 626.15 | 513.47 | 436.15 |
Gross Profit | 1,986 | 1,955 | 2,240 | 1,818 | 1,733 |
Selling, General & Admin | 947.93 | 986.63 | 1,035 | 871.18 | 942.68 |
Research & Development | 219.45 | 201.29 | 254.68 | 166.01 | 166.54 |
Other Operating Expenses | 9.8 | 0.68 | 17.21 | 19.32 | 19.47 |
Operating Expenses | 1,186 | 1,196 | 1,327 | 1,062 | 1,133 |
Operating Income | 800.39 | 759.09 | 912.92 | 755.7 | 599.3 |
Interest Expense | -1.93 | -2.4 | -1.87 | -1.52 | -1.62 |
Interest & Investment Income | 21.68 | 20.42 | 5.89 | 9.61 | 11.52 |
Currency Exchange Gain (Loss) | -2.97 | 0.08 | 0.86 | 0.06 | 3.92 |
Other Non Operating Income (Expenses) | -3.36 | -2.79 | -1.11 | 26.47 | -12.29 |
EBT Excluding Unusual Items | 813.81 | 774.4 | 916.69 | 790.32 | 600.83 |
Impairment of Goodwill | - | - | - | - | -322.6 |
Gain (Loss) on Sale of Investments | 1.88 | 10.52 | -15.44 | 19.86 | -2.24 |
Gain (Loss) on Sale of Assets | 6.3 | 1.09 | 0.12 | -1.2 | 1.68 |
Asset Writedown | -0.38 | -0.15 | -1.49 | -4.47 | -0.84 |
Other Unusual Items | 11.55 | 17.16 | 20.05 | 29.34 | 18.28 |
Pretax Income | 833.16 | 803.02 | 919.93 | 833.85 | 295.12 |
Income Tax Expense | 85.82 | 87.18 | 61.34 | 96.19 | 91.73 |
Earnings From Continuing Operations | 747.34 | 715.84 | 858.59 | 737.66 | 203.39 |
Minority Interest in Earnings | -12.15 | -8.89 | -11.36 | -34.4 | 3.24 |
Net Income | 735.19 | 706.95 | 847.23 | 703.26 | 206.63 |
Net Income to Common | 735.19 | 706.95 | 847.23 | 703.26 | 206.63 |
Net Income Growth | 4.00% | -16.56% | 20.47% | 240.35% | -42.44% |
Shares Outstanding (Basic) | 1,671 | 1,683 | 1,674 | 1,635 | 1,589 |
Shares Outstanding (Diluted) | 1,671 | 1,683 | 1,674 | 1,635 | 1,589 |
Shares Change (YoY) | -0.73% | 0.57% | 2.34% | 2.90% | -2.58% |
EPS (Basic) | 0.44 | 0.42 | 0.51 | 0.43 | 0.13 |
EPS (Diluted) | 0.44 | 0.42 | 0.51 | 0.43 | 0.13 |
EPS Growth | 4.76% | -17.03% | 17.72% | 230.77% | -40.91% |
Free Cash Flow | 736.33 | 568.15 | 757.64 | 224.64 | 460.94 |
Free Cash Flow Per Share | 0.44 | 0.34 | 0.45 | 0.14 | 0.29 |
Dividend Per Share | 0.250 | 0.250 | 0.250 | 0.250 | 0.200 |
Dividend Growth | - | - | - | 25.00% | 19.98% |
Gross Margin | 75.04% | 77.08% | 78.15% | 77.97% | 79.89% |
Operating Margin | 30.24% | 29.93% | 31.86% | 32.42% | 27.63% |
Profit Margin | 27.78% | 27.88% | 29.56% | 30.17% | 9.53% |
Free Cash Flow Margin | 27.82% | 22.40% | 26.44% | 9.64% | 21.25% |
EBITDA | 915.31 | 870.9 | 993.44 | 836.21 | 676.71 |
EBITDA Margin | 34.59% | 34.34% | 34.67% | 35.87% | 31.20% |
D&A For EBITDA | 114.93 | 111.8 | 80.52 | 80.5 | 77.41 |
EBIT | 800.39 | 759.09 | 912.92 | 755.7 | 599.3 |
EBIT Margin | 30.24% | 29.93% | 31.86% | 32.42% | 27.63% |
Effective Tax Rate | 10.30% | 10.86% | 6.67% | 11.54% | 31.08% |
Revenue as Reported | 2,647 | 2,536 | 2,866 | 2,331 | 2,169 |
Advertising Expenses | 57.52 | 33.44 | 11.12 | 8.24 | 9.96 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.